Search Medical Condition
Please enter condition
Please choose location from dropdown

Kassel-Harleshausen, Germany Clinical Trials

A listing of Kassel-Harleshausen, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (75) clinical trials

A Study to Assess Efficacy Safety Tolerability and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy

The purpose of this study is to assess efficacy, safety, tolerability, and pharmacokinetics of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP).

Phase

1.14 miles

Learn More »

A Study to Evaluate the Efficacy of RO7046015 in Participants With Early Parkinson's Disease

This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous RO7046015 versus placebo over 52 weeks in participants with early Parkinson's Disease (PD) who are untreated or treated with monoamine oxidase B (MAO-B) inhibitors since baseline. The study will consist of 2 parts: a 52-week, double-blind, ...

Phase

1.14 miles

Learn More »

Study to Evaluate the Efficacy Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's Patients

This will be a double-blind, randomised, placebo-controlled parallel-arm phase II proof of concept in subjects with PD treated with a stable dose of levodopa who are experiencing both end-of-dose wearing off and Levodopa-Induced Dyskinesia (LID)

Phase

1.14 miles

Learn More »

Study to Identify Clinical Imaging and Biologic Markers of Parkinson Disease Progression

PPMI will be a five-year natural history study (a minimum of 3-year involvement for each subject) of de novo idiopathic PD patients and healthy controls. This study will also include a SWEDD (subjects without evidence of dopaminergic deficit)and Prodromal populations. All subjects will be comprehensively assessed at baseline and every ...

Phase

1.14 miles

Learn More »

Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

The primary objective of Enroll-HD is to develop a comprehensive repository of prospective and systematically collected clinical research data (demography, clinical features, family history, genetic characteristics) and biological specimens (blood) from individuals with manifest HD, unaffected individuals known to carry the HD mutation or at risk of carrying the HD ...

Phase N/A

1.14 miles

Learn More »

Study to Assess the Efficacy and Safety of ACT-541468 in Adult and Elderly Subjects With Insomnia Disorder

The main purpose of this study is to assess efficacy and safety of ACT-541468 in subjects with insomnia disorder. Efficacy will be evaluated on sleep onset and sleep maintenance.

Phase

2.18 miles

Learn More »

Factor XA - Inhibition in RENal Patients With Non-valvular Atrial Fibrillation - Observational Registry

This is a prospective registry allowing a structured, non-interventional collection of data. Participating physicians will not be subject to any instructions with regard to the diagnosis and therapy of their patients. All patient treatment is carried out within clinical routine, at the discretion of the physician and according to existing ...

Phase N/A

2.47 miles

Learn More »

Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular Marginal Zone or Mantle Cell Lymphoma.

MAGNIFY (NCT01996865) is a phase 3b, multicenter, open-label study of patients with grades 1-3b or transformed follicular lymphoma (FL), marginal zone lymphoma (MZL), or mantle cell lymphoma (MCL) who received 1 prior therapy and had stage I-IV, measurable disease. ~500 patients are planned for enrollment in 12 cycles of R2 ...

Phase

2.97 miles

Learn More »

Dasatinib Holiday for Improved Tolerability

Dasatinib is indicated in Europe for: Treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase Chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib Ph+ acute lymphoblastic leukemia (ALL) and lymphoid blast CML with ...

Phase

2.97 miles

Learn More »

A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.

This study aims to assess the optimal duration of nilotinib 300 mg BID consolidation treatment, in order that patients remain in treatment-free remission (MR4.0) 12 months after starting the Treatment-Free Remission (TFR) phase of the study. Rationale CP-CML patients who have received 2 or more calendar years of first-line imatinib ...

Phase

2.97 miles

Learn More »